First Quadrant’s Larimar Therapeutics LRMR Stock Holding History

First Quadrant’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-513	Closed	-$20K	–	824
2016 Q4	$20K	Buy	+513	New	+$20.8K	﹤0.01%	796

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Quadrant's LRMR Position: Q1 2017 in Review

First Quadrant sold out of Larimar Therapeutics (LRMR) in Q1 2017, closing a stake of 513 shares — an estimated $20K sold.

First Quadrant first reported a position in LRMR in Q4 2016 and held it in 1 quarter. The position peaked at $20K in Q4 2016. 80 funds tracked by Wall St. Rank hold LRMR as of Q1 2017.

First Quadrant reported no remaining Larimar Therapeutics position as of Q1 2017 after selling out during the quarter.
First Quadrant sold 513 Larimar Therapeutics shares in Q1 2017, an estimated $20K.
First Quadrant first reported a position in Larimar Therapeutics in Q4 2016 and held it in 1 quarter.
First Quadrant's Larimar Therapeutics position peaked at $20K in Q4 2016.
80 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2017.

Based on First Quadrant's 13F filing for Q1 2017, filed 25 Apr 2017.